Literature DB >> 11878916

Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.

Maureen M Goodenow1, Gregory Bloom, Stephanie L Rose, Steven M Pomeroy, Patricia O O'Brien, Elena E Perez, John W Sleasman, Ben M Dunn.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) protease activity is targeted at nine cleavage sites comprising different amino acid sequences in the viral Gag-Pol polyprotein. Amino acid polymorphisms in protease and in regions of Gag, particularly p7(NC) and the C-cleavage site between p2 and p7(NC), occur in natural variants of HIV-1 within infected patients. Studies were designed to examine the role of natural polymorphisms in protease and to identify determinants in Gag that modulate protease processing activity. Closely related Gag-Pol regions from an HIV-1-infected mother and two children were evaluated for processing in an inducible expression system, for protease activity on cleavage-site analogues, and for impact on replication by recombinant viruses. Gag-Pol regions displayed one of three processing phenotypes based on the appearance of Gag intermediates and accumulation of mature p24(CA). Gag-Pol regions that were processed rapidly to produce p24(CA) resulted in high-level replication by recombinant viruses, while slow-processing Gag-Pol variants resulted in recombinant viruses that replicated with reduced kinetics in both T cell lines and peripheral blood mononuclear cells. Direct impact by Gag sequences on processing by protease was assessed by construction of chimeric Gag-Pol regions and by site-directed mutagenesis. Optimal protease activity occurred when Gag and Pol regions were derived from the same gag-pol allele. Heterologous Gag regions generally diminished rates and extent of protease processing. Natural polymorphisms in novel positions in p7(NC) and the C-cleavage site have a dominant effect on protease processing activity. Accumulation of Gag products after processing at the C site appears to delay subsequent cleavage and production of mature p24(CA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11878916     DOI: 10.1006/viro.2001.1184

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.

Authors:  José C Clemente; Roxana M Coman; Michele M Thiaville; Linda K Janka; Jennifer A Jeung; Sarawut Nukoolkarn; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Robert McKenna; Wichet Leelamanit; Maureen M Goodenow; Ben M Dunn
Journal:  Biochemistry       Date:  2006-05-02       Impact factor: 3.162

2.  Expression, purification and preliminary X-ray crystallographic studies of the human immunodeficiency virus 1 subtype C protease.

Authors:  Roxana M Coman; Arthur Robbins; Maureen M Goodenow; Robert McKenna; Ben M Dunn
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-03-30

3.  Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children.

Authors:  Carina A Rodriguez; Sarah Koch; Maureen Goodenow; John W Sleasman
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

4.  Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.

Authors:  Sarah K Ho; Elena E Perez; Stephanie L Rose; Roxana M Coman; Amanda C Lowe; Wei Hou; Changxing Ma; Robert M Lawrence; Ben M Dunn; John W Sleasman; Maureen M Goodenow
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

5.  Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.

Authors:  Sarah K Ho; Roxana M Coman; Joshua C Bunger; Stephanie L Rose; Patricia O'Brien; Isabel Munoz; Ben M Dunn; John W Sleasman; Maureen M Goodenow
Journal:  Virology       Date:  2008-07-02       Impact factor: 3.616

Review 6.  Retroviral proteases.

Authors:  Ben M Dunn; Maureen M Goodenow; Alla Gustchina; Alexander Wlodawer
Journal:  Genome Biol       Date:  2002-03-26       Impact factor: 13.583

7.  Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potency.

Authors:  Nathan E Goldfarb; Meray Ohanessian; Shyamasri Biswas; T Dwight McGee; Brian P Mahon; David A Ostrov; Jose Garcia; Yan Tang; Robert McKenna; Adrian Roitberg; Ben M Dunn
Journal:  Biochemistry       Date:  2015-01-07       Impact factor: 3.162

8.  Genetic Diversity and Low Therapeutic Impact of Variant-Specific Markers in HIV-1 Pol Proteins.

Authors:  Paloma Troyano-Hernáez; Roberto Reinosa; Africa Holguín
Journal:  Front Microbiol       Date:  2022-07-14       Impact factor: 6.064

9.  New findings in cleavage sites variability across groups, subtypes and recombinants of human immunodeficiency virus type 1.

Authors:  Esther Torrecilla; Teresa Llácer Delicado; África Holguín
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

10.  Molecular Docking-Based Screening for Novel Inhibitors of the Human Immunodeficiency Virus Type 1 Protease that Effectively Reduce the Viral Replication in Human Cells.

Authors:  Carla Mavian; Roxana M Coman; Xinrui Zhang; Steve Pomeroy; David A Ostrov; Ben M Dunn; John W Sleasman; Maureen M Goodenow
Journal:  J AIDS Clin Res       Date:  2021-05-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.